Skip to main content
. 2015 Apr 2;2015:905019. doi: 10.1155/2015/905019

Table 2.

Summary of changes in pain score (NRS-11) from baseline within each test group.

6-week score (Tx cessation) 10-week score (4 weeks after Tx cessation)
Pain score adjusted means % reduction from baseline Pain score adjusted means % reduction from baseline
Group A
 Evaporative 3.82 12% 3.50 19%
 Tactile 1.60 26% 2.14 −6.10%
 Hypertonic 1.42 33% 1.22 42%
 CMS 2.26 20% 2.30 18%
Group B
 Evaporative 3.51 19% 2.97 31%
 Tactile 1.22 40% 1.27 37%
 Hypertonic 1.24 41% 0.92 56%
 CMS 1.97 30% 1.69 40%
Group C
 Evaporative 2.39 45% 2.89 33%
 Tactile 1.11 32% 1.74 14%
 Hypertonic 1.26 40% 1.65 22%
 CMS 1.65 42% 2.14 24%
Group D
 Evaporative 2.48 43% 2.46 43%
 Tactile 0.77 62% 0.72 64%
 Hypertonic 0.83 61% 0.73 66%
 CMS 1.35 52% 1.29 54%

Group A: Colgate Cavity Protection; Group B: Sensodyne Total Care; Group C: Clinpro Tooth Crème (brushing only); Group D: Clinpro Tooth Crème (brushing and topical application). A positive value of percentage change indicates an improvement in sensitivity at the time of assessment compared to baseline.

CMS: combined modalities score is the average of all testing modalities, evaporative, tactile, and hypertonic.

Adjusted baseline means from ANCOVA: evaporative = 4.35; tactile = 2.00; hypertonic = 2.12; CMS = 2.83.